Clinical Trial

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant chemotherapy
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-15
Trial Details
NCT Number NCT07400523
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Breast Cancer
Enrollment 446 participants
Start Date 2026-02-10
Primary Completion 2030-02-10 (estimated)
Study Completion 2031-02-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-28